Disease: Opioid dependence

Adults who microdose psychedelics report health related motivations and lower levels of anxiety and depression compared to non-microdosers

This large international study of over 8,700 people found that adults who microdose psychedelics report taking small doses for health and wellness reasons. Among people with anxiety or depression, microdosers showed lower symptom levels than non-microdosers. Most microdosers used psilocybin and combined it with other substances like Lion’s Mane mushrooms or niacin, practices they refer to as stacking.

Read More »

Sex-specific role of the 5-HT2A receptor in psilocybin-induced extinction of opioid reward

Researchers discovered that a single dose of psilocybin can reduce opioid addiction-related behaviors in male mice by activating serotonin receptors in specific brain circuits, but this effect does not work the same way in females. The study reveals that psilocybin changes how the brain processes opioid rewards and withdrawal symptoms, suggesting psychedelics could become a new treatment approach for opioid addiction. However, important sex differences in how the brain responds mean treatments may need to be tailored differently for men and women.

Read More »

Psychedelics: From Cave Art to 21st-Century Medicine for Addiction

This comprehensive review examines how psychedelic substances, from magic mushrooms to LSD, are being studied as treatments for addiction. After decades of restriction, researchers are rediscovering what indigenous cultures have known for thousands of years: these substances can help people overcome alcohol, drug, and tobacco addiction. The research shows promising results, particularly when combined with therapy, with abstinence rates significantly higher than traditional treatments.

Read More »
Scroll to Top